Is Curcumin/Turmeric Safe for Cancer Patients?

Curcumin is one of the most well-established botanicals. In fact, it's one of the five key compounds we use to help block the metabolic pathways cancer relies on to grow. So when headlines started circulating about turmeric and curcumin supplements causing liver damage, we started getting questions from patients who'd been warned off turmeric entirely, sometimes forbidden from taking it, by their own oncologists. So in this article, we're sharing our own findings after digging into the studies behind the headlines.

Our conclusion is that the concern has been significantly overblown, but it's important to know why so you can help make an informed decision with your doctor.

What Curcumin Is and Why We Recommend It

Curcumin is the primary active compound in turmeric (Curcuma longa), a plant that's been used medicinally in India for thousands of years. Its therapeutic reputation rests on well-documented anti-inflammatory, antioxidant, detoxification-supporting and immuno-modulatory properties.

Within the metabolic theory of cancer, curcumin is one of the botanicals we use as part of a broader strategy to interrupt the metabolic pathways cancer cells depend on. This is why it sits alongside quercetin, berberine and a small group of other compounds in what we consider a core part of our integrative approach, used to complement (not replace) conventional treatment.

Where the Liver Injury Headlines Come From

The concern isn't manufactured out of nothing; it's based on real case reports. The US Drug-Induced Liver Injury Network (DILIN) documented ten cases of turmeric-associated liver injury between 2004 and 2022, six of which occurred since 2017 [1]. Similar cases have been reported in Australia, enough that our own Therapeutic Goods Administration (TGA) issued a formal advisory, having received 18 reports of liver problems in people taking turmeric or curcumin products, with two classified as severe including one fatal outcome [2].

That's worth taking a closer look. But what gets lost when a headline says "turmeric causes liver damage" is what these cases actually have in common, and it isn't simply "people took curcumin."

Bioavailability boosters appear to be the real common thread. Curcumin on its own is notoriously poorly absorbed, which is exactly why many supplement brands add piperine (black pepper extract) to increase absorption, in some cases by up to 2,000% [3]. A striking number of the published liver injury case reports specifically involve turmeric-plus-piperine combination products or other high-bioavailability formulations such as liposomal preparations [3][4].

So the honest summary: a small handful of case reports worldwide, against a supplement category used by tens of millions of people, clustering heavily around one specific and avoidable pattern; high-dose, bioavailability-boosted extracts. That's not evidence curcumin itself is dangerous. It's evidence that a particular type of product deserves a closer look, which is a very different and far less alarming conclusion.

Putting the Risk in Perspective

It's worth being precise about where the recent wave of headlines actually came from, because the source is a bit different than it appears. Much of the 2024–2025 media coverage traces back to a JAMA Network Open study that estimated how many US adults use botanicals with some documented liver injury signal: turmeric, green tea extract, ashwagandha, Garcinia cambogia, red yeast rice and black cohosh, combined [7]. That paper found roughly 15.6 million US adults had used at least one of these six products in the past month, a figure comparable to usage of common statins or NSAIDs [7]. That's a study about exposure, not about how many people were harmed, but headlines like "millions at risk" collapsed that distinction, and several commentators have since pointed out the coverage significantly overstated what the paper actually showed [8].

When you isolate turmeric specifically and look only at confirmed injury cases, the picture is genuinely reassuring: the DILIN registry recorded 10 turmeric-associated cases over a 12-year window (2011–2022) [1], under one case per year, against a user base in the tens of millions. About half of those cases were mild and didn't require hospitalisation, and several involved people who were also overweight or regular alcohol users, additional load on the liver that makes it harder to pin the injury on curcumin alone.

For context, it's worth setting that against a household over-the-counter medication most people take without a second thought. Acetaminophen (Tylenol/paracetamol) overdose is the leading cause of acute liver failure in the US, responsible for somewhere in the range of 50,000 to 56,000 emergency room visits, roughly 2,600 hospitalisations, and around 450 to 500 deaths every year [9].

So a supplement generating fewer than one confirmed liver injury case per year gets "millions at risk" headlines, while a medicine cabinet staple involved in hundreds of deaths annually barely makes the news. When we actually looked at the numbers behind the headlines, our take is that this is a case of the coverage running well ahead of the evidence.

What This Means If You're on Chemotherapy or Other Cancer Treatment

There's a second, separate question worth addressing: does curcumin interact with cancer drugs themselves?

In lab studies, curcumin inhibits liver enzymes involved in metabolising a number of chemotherapy agents [5]. In theory, that could raise or lower drug levels depending on the specific agent. In practice, clinical studies pairing curcumin with taxane chemotherapy haven't shown the drug-level changes lab data predicted, largely because curcumin's poor oral bioavailability means it typically doesn't reach high enough systemic levels to meaningfully interact with those enzymes [6].

That said, there are specific situations where we advise against curcumin use:

• If you're taking cyclophosphamide, trametinib (Mekinist), or dabrafenib (Tafinlar)

• If you're taking Tamoxifen

• If you have biliary obstruction or jaundice

• If you have anaemia, as curcumin can bind iron and worsen it

• If you have low platelets or an elevated bleeding risk, including pre-operatively

• If you're an active tobacco smoker, as curcumin can act as a carcinogen in this context

  
  

As always, run any supplement decision past your treating oncology team, who can check it against your specific drug regimen.

A Note on Form

We recommend getting turmeric into your diet as often as possible in food form: cooked meals, salad dressings, and if you're making our carrot and ginger juice, raw turmeric root in the same quantity as ginger. There's no meaningful liver injury signal at culinary doses, and turmeric's anti-inflammatory benefits are well worth the daily habit.

For supplementation, form matters more than most people realise, given the bioavailability issue discussed above. Many brands make bold absorption claims that aren't backed by truly independent testing, so it's important to choose carefully. Of the options available, we consider phytosomal curcumin to be the best form for absorption and consistency. The right dose for your specific situation is something we work through individually with our patients and cover in detail in our program, since it genuinely depends on your treatment, your bloodwork, and what else you're taking.

Watch for jaundice, unusual fatigue, dark urine, pale stools, itching or upper right abdominal discomfort. Given the typical one-to-four-month delayed onset seen in the case reports, this is worth keeping in mind even well after you've settled into a routine, not just in the first week or two.

Conclusion

Curcumin remains one of the better-studied botanicals we use in integrative cancer care, with a genuinely long history of safe traditional use and a strong rationale for its role in reducing inflammation and supporting the body during treatment. Having looked closely at the actual case data behind the headlines, our view is that the current level of alarm simply isn't supported by the evidence: a small number of cases, clustered around a specific and identifiable pattern, against a backdrop of enormous and largely uneventful use. That's not a reason to avoid curcumin. It's a reason to work with a practitioner who understands the full picture, rather than avoiding one of the most useful compounds we can recommend out of headline-driven fear.

---

References

1. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver Injury Associated with Turmeric: A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network. The American Journal of Medicine. 2023. doi:10.1016/j.amjmed.2022.09.026

2. Therapeutic Goods Administration. Safety advisory: turmeric and curcumin products and risk of liver injury. Australian Government Department of Health.

3. Dennis K. Turmeric Supplements and Liver Toxicity. NutritionFacts.org. August 2025. https://nutritionfacts.org/video/turmeric-supplements-and-liver-toxicity/

4. Koo et al. Drug-Induced Liver Injury Secondary to Turmeric Supplement Containing Piperine: A Case Report. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12633785/

5. When Nature Meets Oncology: Unraveling Herb-Drug Interactions in Cancer Therapy. International Journal of Molecular Sciences. 2025. https://www.mdpi.com/1422-0067/26/21/10494

6. You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment. Pharmacy Times. 2026. https://www.pharmacytimes.com/view/you-shall-not-pass-pharmacist-review-of-drug-herb-interactions-in-cancer-treatment-ppfo

7. Likhitsup A, Chen VL, Fontana RJ. Estimated Exposure to 6 Potentially Hepatotoxic Botanicals in US Adults. JAMA Network Open. 2024;7(8):e2425822. doi:10.1001/jamanetworkopen.2024.25822

8. JAMA Paper Exaggerates Liver Injury Risk of Several Herbal Dietary Supplements. GlobeNewswire commentary. August 2024. https://www.globenewswire.com/news-release/2024/08/10/2927990/0/en/JAMA-Paper-Exaggerates-Liver-Injury-Risk-of-Several-Herbal-Dietary-Supplements.html

9. Acetaminophen Toxicity. StatPearls, NCBI Bookshelf. Updated 2026. https://www.ncbi.nlm.nih.gov/books/NBK441917/